Wandercraft's Atalante X receives second FDA clearance
Evidence notes
- • Wandercraft received FDA clearance for Atalante X for rehabilitation in individuals with spinal cord injuries at levels T5 to L5.
- • This follows the device's previous clearance for stroke rehabilitation in December 2022.
- • The clearance is supported by data from over 500 patients, including clinical trials and real-world evidence.
Company context
Develops self-balancing robotic exoskeletons designed to restore walking ability for people with mobility impairments. The systems use dynamic stabilization to enable hands-free locomotion without crutches or walkers.